Zydus Lifesciences moves up as its arm launches generic of phenylpropanolamine hydrochloride tablets

16 Sep 2025 Evaluate

Zydus Lifesciences is currently trading at Rs. 1038.35, up by 1.65 points or 0.16% from its previous closing of Rs. 1036.70 on the BSE.

The scrip opened at Rs. 1037.35 and has touched a high and low of Rs. 1043.35 and Rs. 1034.60 respectively. So far 9063 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1135.95 on 16-Sep-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1054.55 and Rs. 1030.50 respectively. The current market cap of the company is Rs. 104331.37 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.26% and 6.74% respectively.

Zydus Lifesciences’ step down wholly owned subsidiary – ZyVet Animal Health has released the first FDA-approved generic of phenylpropanolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs. This latest product underscores ZyVet’s mission to bring trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.

Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and aging dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents. ZyVet’s generic provides dependable symptom relief while supporting stronger long-term client compliance. Available in multiple strengths to support precise dosing, the product is designed with the needs of both veterinary teams and pet owners in mind. 

ZyVet’s rapid portfolio expansion leads a paradigm shift in the industry reinforcing that generic animal health products are as effective as the pioneer brands. As a division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical, R&D, Regulatory, QA/QC, manufacturing scale, excellence and expertise. ZyVet Animal Health, a leader in affordable generic pharmaceuticals for animals, is a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

911.50 -5.95 (-0.65%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×